Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2012 1
2016 2
2017 1
2018 2
2019 3
2021 3
2022 7
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacology and pharmacokinetics of elacestrant.
Beumer JH, Foldi J. Beumer JH, et al. Among authors: foldi j. Cancer Chemother Pharmacol. 2023 Aug;92(2):157-163. doi: 10.1007/s00280-023-04550-7. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314500
CDK4/6 inhibitors: The Devil is in the Detail.
Magge T, Rajendran S, Brufsky AM, Foldi J. Magge T, et al. Among authors: foldi j. Curr Oncol Rep. 2024 Jun;26(6):665-678. doi: 10.1007/s11912-024-01540-7. Epub 2024 May 7. Curr Oncol Rep. 2024. PMID: 38713311 Review.
Cancer Relevance of Human Genes.
Qing T, Mohsen H, Cannataro VL, Marczyk M, Rozenblit M, Foldi J, Murray M, Townsend JP, Kluger Y, Gerstein M, Pusztai L. Qing T, et al. Among authors: foldi j. J Natl Cancer Inst. 2022 Jul 11;114(7):988-995. doi: 10.1093/jnci/djac068. J Natl Cancer Inst. 2022. PMID: 35417011 Free PMC article.
Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM, Marczyk M, Karn T, Qing T, Li X, Gunasekharan V, Yaghoobi V, Bai Y, Ibrahim EY, Park T, Silber A, Wolf DM, Reisenbichler E, Denkert C, Sinn BV, Rozenblit M, Foldi J, Rimm DL, Loibl S, Pusztai L. Blenman KRM, et al. Among authors: foldi j. Clin Cancer Res. 2022 Jun 13;28(12):2587-2597. doi: 10.1158/1078-0432.CCR-21-3215. Clin Cancer Res. 2022. PMID: 35377948 Free PMC article. Clinical Trial.
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer.
Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini OD, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G. Licata L, et al. Among authors: foldi j. NPJ Breast Cancer. 2023 Jun 8;9(1):51. doi: 10.1038/s41523-023-00559-6. NPJ Breast Cancer. 2023. PMID: 37291235 Free PMC article.
Comprehensive Analysis of Metabolic Isozyme Targets in Cancer.
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Marczyk M, et al. Among authors: foldi j. Cancer Res. 2022 May 3;82(9):1698-1711. doi: 10.1158/0008-5472.CAN-21-3983. Cancer Res. 2022. PMID: 35247885 Free PMC article.
28 results